Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
20 août 2018 08h19 HE
|
Taiwan Liposome Company, Ltd.
Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...
TLC Reports Last Patient Last Visit (LPLV) in TLC599 Phase II Trial and FDA Clearance to Commence New Clinical Trials
09 juil. 2018 15h01 HE
|
Taiwan Liposome Company, Ltd.
LPLV marks the final steps toward completion of TLC599 trial for osteoarthritis (OA) painPhase II topline results on-track for 2018 releaseSet to initiate enrollment of US Phase II pharmacokinetic...